Description
The abstract identifies SMPD1 as regulating sphingomyelin-to-ceramide conversion and shows fluoxetine inhibits EGFR signaling, but the molecular pathway connecting these events is unclear. This mechanistic gap limits rational drug design and combination strategies.
Gap type: unexplained_observation Source paper: Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. (None, None, PMID:34731610)